Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
N07XX12
|
| gptkbp:developer |
gptkb:Alnylam_Pharmaceuticals
|
| gptkbp:drugClass |
small interfering RNA
|
| gptkbp:firstBook |
yes
|
| gptkbp:form |
lipid nanoparticle
|
| gptkbp:genericName |
gptkb:patisiran
|
| https://www.w3.org/2000/01/rdf-schema#label |
Onpattro (2018)
|
| gptkbp:indication |
hereditary transthyretin-mediated amyloidosis
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gptkb:RNA_interference
|
| gptkbp:orphanDrug |
yes
|
| gptkbp:pregnancyCategory |
not assigned
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
peripheral edema
infusion-related reactions upper respiratory tract infections |
| gptkbp:target |
gptkb:transthyretin_mRNA
|
| gptkbp:bfsParent |
gptkb:Alnylam_Pharmaceuticals,_Inc.
|
| gptkbp:bfsLayer |
8
|